Dynomics B.V.

Dynomics B.V. P.O. Box 82 1400 AB Bussum Website Dynomics B.V. E-mail Dynomics B.V. T +31 (0)10 704 40 94 F +31 (0)10 704 47 31 Employees in Amsterdam: Employees in R&D: Year of foundation: 2001

Company Profile

Dynomics aims to be the worldwide leader in the development of tests that provide diagnostic information on the classification of leukemia and lymphoma and information on the prognosis and staging of the disease.
The developed tests present the clinician with a meaningful improvement over current methods for diagnosing leukemia and lymphoma.

Science and Technologies or Services

Currently available diagnostic tests for leukemia diagnosis are relatively expensive and take a long processing times (at least 2 to 3 days). It is important for a diagnostic test to provide rapid results. Also the precise classification of leukemia has major implications for prognosis, treatment choice and dosage. For example, the Dynomics' multiplex single tube assay for detection and identification of fusion proteins derived from chromosome aberrations provides a result in a few hours, whereas the traditional tests for detection of chromosome with fusion genes can take up to several days. Once the treatment has been chosen, the physician can monitor the effectiveness of the leukemia treatment during follow-up with the Dynomics' single fusion tube protein detection kit.
Dynomics is working on the development of the first kit for disease (sub-) classification and progression measurement and on kits containing antibodies against molecules in lymphoid development for (sub) classification of leukemias and lymphoma and possibly for evaluation of B-cell and T-cell subsets in auto-immune diseases and allergies.

Alliances

Dynomics BV works together with the Erasmus Medical Center, and with many life sciences companies and large pharma.

Keywords

• Leukemia
• Lymphomas
• Cancer
• Fusion Proteins
• Drug Discovery
• Diagnostics.